Business Context and Reporting Period
Company: MedaSorb Technologies Corporation (operating subsidiary: CytoSorbents, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Status: Development stage company; no commercial revenue generated to date.
Primary Activity: Research, development, and commercialization of the CytoSorb blood purification device, currently focused on a clinical trial in Europe for the treatment of sepsis.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 | Balance Sheet (Mar 31, 2009) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(760,151) | $(646,050) | N/A |
| Accumulated Deficit | N/A | N/A | $(76,392,206) |
| Cash and Cash Equivalents | N/A | N/A | $2,154,795 |
| Total Current Liabilities | N/A | N/A | $893,067 |
| Notes Payable (Current) | N/A | N/A | $50,000 |
| Net Cash Used in Operating Activities | $(784,111) | $(259,807) | N/A |
Material Changes vs. Prior Period
- Increased Losses: Net loss increased by approximately 18% to $760,151 in Q1 2009 compared to $646,050 in Q1 2008.
- Expense Growth: Research and development expenses rose to $488,555 from $355,127. General and administrative expenses decreased slightly to $228,334 from $233,524.
- Cash Burn: Net cash used in operating activities increased significantly to $784,111 from $259,807 in the prior year quarter.
- Equity Activity: The company issued stock dividends totaling $170,574 in Series A and Series B preferred stock. Additionally, 5,247,302 shares of preferred stock were converted into common stock during the period.
- Debt Reduction: Long-term notes payable of $50,000 were reclassified to current liabilities; no new long-term debt was incurred.
Outlook, Risks, and Management Commentary
- Going Concern: The company has an accumulated deficit of over $76 million and relies on future financing. Auditors have expressed substantial doubt about the company's ability to continue as a going concern.
- Liquidity: Management believes cash on hand ($2.15 million) is sufficient to fund operations through the third quarter of 2009. Additional funding will be required to complete clinical studies and commercialization.
- Clinical Progress: The European clinical trial for CytoSorb (sepsis indication) has enrolled 23 patients across 10 hospital sites. The protocol was revised to allow up to 100 patients. Management anticipates CE Mark approval in the first half of 2010, assuming successful study outcomes and adequate funding.
- Legal Proceedings: A trademark dispute with Alkermes, Inc. regarding the name "MedaSorb" was settled in June 2008. The operating subsidiary was renamed CytoSorbents, Inc. to avoid confusion.
- Risk Factors: Risks include failure to obtain regulatory approvals (FDA/CE Mark), inability to secure future financing, and potential patent infringement litigation which could trigger the issuance of up to 10 million additional common stock warrants.
Investor Verification Checklist
- Runway: Verify if the $2.15 million cash balance is sufficient to reach the projected Q3 2009 funding deadline given the current burn rate of ~$784k/quarter.
- Financing Terms: Review the terms of the $50,000 convertible notes and the potential dilution from the 10 million contingent warrants related to patent litigation.
- Clinical Milestones: Monitor the enrollment rate of the European clinical trial and the timeline for the CE Mark submission.
- Preferred Stock: Assess the impact of the 10% Series A and Series B preferred stock dividends on common shareholders.
- Regulatory Status: Confirm the current status of the FDA pilot study approval versus the European CE Mark strategy.